BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Inclusion Criteria: * PHASE I: Patients must have histologically confirmed WHO grade II-III glioma that is progressive or recurrent following at least one prior chemotherapy regimen plus or minus radiation therapy regimen or (b) Grade IV disease in their recurrent resection or biopsy specimen or (c) Grade IV glioma at initial diagnosis, with recurrent disease. Phase I patients may have failed an unlimited number of prior systemic regimens. * PHASE II: Patients must have histologically confirmed WHO grade II-IV glioma that is progressive or recurrent following therapy: * Arm A patients must have WHO grade II-III glioma and have failed TMZ and another alkylator (e.g., carmustine, lomustine, procarbazine). Patients in Arm A may have failed an unlimited number of prior systemic regimens. Prior radiotherapy (RT) is not required for eligibility. There is no minimum time from the last antineoplastic treatment, except to allow for recovery: three weeks from last dose of TMZ and six weeks from last dose of nitrosourea. * Arm B patients must have WHO grade II-III glioma and have experienced tumor progression after TMZ or another alkylator (maximum one prior chemotherapy regimen), and have gone \>= 12 months since last treatment (chemotherapy or RT). Prior radiation therapy (RT) is allowed but not mandated. * GBM Arm patients must have WHO grade IV glioblastoma following radiotherapy (45-60 gray \[Gy\] in 1.8-2.0 Gy fractions) plus chemotherapy and may have failed an unlimited n…